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PURPOSE. The purpose of this study was to investigate the phenotype and long-term clinical
course of female carriers of RPGR mutations.
METHODS. This was a retrospective cohort study of 125 heterozygous RPGR mutation carriers
from 49 families.
RESULTS. Eighty-three heterozygotes were from retinitis pigmentosa (RP) pedigrees, 37 were
from cone-/cone-rod dystrophy (COD/CORD) pedigrees, and 5 heterozygotes were from
pedigrees with mixed RP/CORD or unknown diagnosis. Mutations were located in exon 1-14
and in ORF15 in 42 of 125 (34%) and 83 of 125 (66%) subjects, respectively. The mean age at
the first examination was 34.4 years (range, 2.1 to 86.0 years). The median follow-up time in
heterozygotes with longitudinal data (n ¼ 62) was 12.2 years (range, 1.1 to 52.2 years).
Retinal pigmentary changes were present in 73 (58%) individuals. Visual symptoms were
reported in 51 (40%) cases. Subjects with both symptoms and pigmentary fundus changes
were older than the other heterozygotes (P ¼ 0.01) and had thinner foveal outer retinas (P ¼
0.006). Complete expression of the RP or CORD phenotype was observed in 29 (23%)
heterozygotes, although usually in milder forms than in affected male relatives. Best-corrected
visual acuity (BCVA) was <20/40 and <20/400 in at least one eye in 45 of 116 (39%) and 11 of
116 (9%) heterozygotes, respectively. Myopia was observed in 74 of 101 (73%) subjects and
was associated with lower BCVA (P ¼ 0.006). Increasing age was associated with lower BCVA
(P ¼ 0.002) and decreasing visual field size (P ¼ 0.012; I4e isopter).
CONCLUSIONS. RPGR mutations lead to a phenotypic spectrum in female carriers, with myopia
as a significantly aggravating factor. Complete disease expression is observed in some
individuals, who may benefit from future (gene) therapeutic options.
Keywords: retinitis pigmentosa GTPase regulator, retinitis pigmentosa, gene therapy, disease
progression
Pathogenic variants in the RPGR gene are associated with awide variety of severe X-linked retinal degenerations in
male patients, including retinitis pigmentosa (RP3), cone-rod
dystrophy (CORD), and isolated cone dystrophy (COD).1–4
Female carriers of X-linked RP usually experience no or mild
symptoms and signs of ocular involvement.5,6 However,
variable degrees of disease expression have been reported,2,7–10
and a few studies have shown a correlation between fundus
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features and retinal function measures.10,11 A pathognomic
retinal feature in carriers of X-linked RP is the tapetal-like
reflex,5 a golden metallic-luster sheen of the perimacular
retina, but this is often absent or only seen in a subset of female
carriers of RPGR mutations.8,12,13
Although a wide spectrum of severity has been described in
female carriers from RP pedigrees, female carriers from RPGR-
associated COD/CORD pedigrees usually display no or mild
fundus abnormalities.14,15 Genotype–phenotype correlations in
female carriers of pathogenic variants in RPGR, linking the
genotype to the degree of disease expression, have rarely been
described, as large cohorts of female heterozygotes are scarce.10
The recent initiation of a human gene therapy trial for
RPGR-associated retinal dystrophies in male patients offers a
promising therapeutic perspective (ClinicalTrials.gov number:
NCT03116113).16 An optimal insight into the clinical charac-
teristics and variability of disease expression in female carriers
of pathogenic RPGR variants becomes increasingly important
to further understand the phenotypic spectrum. The purpose
of this study was to expand our knowledge of the initial and
longitudinal clinical characteristics of a large cohort of female
carriers of pathogenic RPGR variants and to assess whether
upcoming RPGR gene therapy trials may consider the inclusion
of affected female carriers.
MATERIALS AND METHODS
Study Population
This study identified female carriers of disease-causing RPGR
variants who underwent at least one clinical examination.
Inclusion criteria were a molecular confirmation of an RPGR
mutation or an obligate carrier status. Additionally, two
subjects had not undergone molecular genetic analysis, but
an RPGR mutation was molecularly confirmed in a first-degree
relative, along with the presence of a tapetal-like reflex in the
female subject, which is considered a pathognomonic sign of
XLRP carriership.11,17
Obligate carriers were defined as daughters of an affected
father, mothers of at least two affected sons, or mothers of one
affected son along with at least one other affected male patient
or confirmed carrier in the family, to exclude the possibility of
a de novo mutation.
Heterozygotes were collected from the database (Delleman
database) for genetic eye diseases at the Academic Medical
Center (AMC) in Amsterdam, from various other Dutch medical
centers within the framework of the RD5000 consortium,18 and
from the Ghent University Hospital in Belgium. Of the 125
included female carriers of pathogenic RPGR variants, 21 were
from a large Dutch pedigree that has been previously
described,14 and additional follow-up data since the publication
of that study were available in three subjects.
The study was approved by the Medical Ethics Committee of
the Erasmus Medical Center for the Dutch subjects and by the
Ethics Committee of Ghent University Hospital for the Belgian
subjects and adhered to the tenets of the Declaration of Helsinki.
Dutch participants provided informed consent for the use of their
clinical data for research purposes. In Dutch subjects who were
no longer traceable, the subject-specific information was deleted
after data collection and the subjects were pseudonymized. For
Belgian subjects, the local Ethics Committee waivered the need
for informed consent on the condition of pseudonymization.
Genetic Analysis
Of the 125 heterozygotes, 108 had received molecular
confirmation of their carrier status through Sanger direct
sequencing (n ¼ 71), linkage analyses (n ¼ 35), or whole
exome sequencing (n ¼ 2), 15 were obligate carriers with no
further molecular analysis, and 2 nonobligate carriers had a
tapetal-like reflex and were first-degree relatives to patients
who had received genetic confirmation of an RPGR mutation.
Mutational analyses were performed at the AMC in Amsterdam,
The Netherlands (n ¼ 77), the Radboud University Medical
Center in Nijmegen, The Netherlands (n¼2), Ghent University
Hospital, Ghent, Belgium (n¼14), or at the Manchester Centre
for Genomic Medicine, Manchester, United Kingdom (n¼ 15).
Clinical Data Collection
Medical records were reviewed for symptoms, best-corrected
visual acuity (BCVA), biomicroscopy, fundus examination, full-
field dark- and light-adapted single flash and 30-Hz electroreti-
nography (ffERG) according to the International Society for
Clinical Electrophysiology of Vision standards,19 Goldmann visual
field (GVF) examination, spectral-domain optical coherence
tomography (SD-OCT), and fundus autofluorescence (FAF) where
available. Color vision testing was performed in 45 subjects, using
Hardy-Rand-Rittler plates (n ¼ 24), Ishihara plates (n ¼ 26),
Farnsworth Panel D15 testing (n ¼ 33), and Farnsworth Tritan
plates (n¼23). GVF areas of the V4e and I4e target were digitized
and converted to seeing retinal areas in mm2, using a method
described by Dagnelie.20 Not all subjects underwent all clinical
examinations. All FAF images and most SD-OCT images (n¼ 41)
were obtained with the Heidelberg Spectralis (Heidelberg
Engineering, Heidelberg, Germany). For these patients, retinal
thickness measurements and segmentation analyses were ob-
tained using the Spectralis software, measuring the total central
retinal thickness (from the inner limiting membrane to the basal
membrane), outer nuclear layer thickness, and the outer retinal
thicknessþ PRE complex (from the external limiting membrane
to the basal membrane). In the other three subjects, SD-OCT
images were taken with the Topcon (n¼1; 3D OCT-1000; Topcon
Medical Systems, Tokyo, Japan) or Zeiss CIRRUS version 6.0 (n¼
2; Carl Zeiss Meditec, Inc., Dublin, CA, USA).
We categorized fundus status based on previously used
criteria,10,11 using clinical notes and fundus photographs:
grade 0 (no fundus abnormalities); grade 1 (a tapetal-like reflex
without pigmentary changes in the retina); grade 2 (regional
pigmentary changes, e.g., bone-spicule–like pigmentation,
involving at least two quadrants, and/or macular RPE
alterations, with or without a tapetal-like reflex); grade 3 (at
least three quadrants of pigmentary changes or RPE atrophy in
the periphery).
Statistical Analysis
Data were analyzed using SPSS version 23.0 (IBM Corp.,
Armonk, NY, USA). BCVA was divided into the following
categories, based on the World Health Organization criteria,
adding a category of ‘‘mild visual impairment’’ (BCVA <20/40
and ‡20/67): normal or subnormal visual acuity (BCVA ‡20/
40), low vision (BCVA <20/67 and ‡20/200), severe visual
impairment (BCVA <20/200 and ‡20/400), and blindness
(BCVA <20/400). For statistical analysis, we converted visual
acuities to logMAR. We used the unpaired t-test, Mann-Whitney
test, and v2 tests to compare means, medians, and proportions,
respectively. Longitudinal changes in BCVA and seeing retinal
area were analyzed using linear mixed models.
RESULTS
One hundred twenty-five female carriers from 49 families were
investigated. Genetic analysis yielded 39 distinct pathogenic
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RPGR variants (Supplementary Table S1). Mutations were
located in exon 1-14 and in ORF15 in 41 of 125 (33%) and 84 of
125 (67%) subjects, respectively. Longitudinal data were
available for 62 of 125 subjects (50%). In these subjects, the
median follow-up time was 12.2 years (interquartile range
[IQR]: 12.8; range, 1.1 to 52.2 years), with a median of 4.5
visits per subject (IQR: 5; range, 2 to 31). The follow-up was
significantly longer (P¼ 0.001) and more frequent (P¼ 0.001)
in subjects with symptoms or pigmentary fundus changes and
in myopic heterozygotes (P ¼ 0.01 and P ¼ 0.002). The mean
age at the first examination was 34.4 years (SD, 17.8; range, 2.1
to 86.0 years).
Symptoms and Fundus Features
Of the 49 families, 36 (73%) comprised at least one
heterozygote with mild to severe symptoms and/or pigmentary
fundus changes. At the most severe end of the spectrum of
RPGR carrier phenotypes, we identified a subset of heterozy-
gotes (n¼ 29; from 23 pedigrees; Supplementary Fig. S1) who
displayed extensive intraretinal pigmentary changes or retinal
atrophy in at least two quadrants (n¼29), usually with macular
RPE alterations or atrophy (26 of 29; 90%), as well as multiple
visual symptoms beyond nyctalopia (n¼ 29), objectified visual
field restriction (27 of 28; 96%; unavailable in n¼ 1), and/or a
BCVA-based visual impairment in at least one eye (23 of 29;
79%), and significantly attenuated scotopic and/or photopic
responses on ERG in all cases where an ERG was available (n¼
24). There was a significant difference (P¼ 0.01) in mean age
between heterozygotes with both symptoms and pigmentary
fundus changes (mean, 45.6 years; SD, 18.1; range, 11.7 to 80.2
years) and the other female carriers (mean, 37.7 years; SD,
15.7; range, 7.0 to 86.0 years).
Symptoms were reported by 51 heterozygotes (41%) and
included variable degrees of nyctalopia (n ¼ 40; 32%),
subjective visual field restriction (n ¼ 17; 14%), subjective
central vision decline (n¼ 29, 23%), and/or photophobia (n¼
20; 16%). The presence of symptoms was not associated with
the location of the mutation (P ¼ 0.20), and no significant
genotype–phenotype correlations were found (Supplementary
Table S2).
The presence or absence of a tapetal-like reflex was
explicitly reported in 60 cases and was found to be present
in 24 of 60 heterozygotes (40%), with no significant age
difference between those with and without a tapetal-like reflex
(P¼ 0.67) and no significant association between the presence
of the tapetal-like reflex and the development of symptoms (P
¼ 0.54) or intraretinal pigmentary changes (P ¼ 0.37).
An adequate assessment of both symptomatology and
fundus features could be made in 117 subjects. Heterozygotes
were asymptomatic and had no pigmentary fundus changes in
35 of 117 cases (30%). Eighty-two heterozygotes (70%) had
some degree of disease expression in the form of symptoms
and/or pigmentary changes (Table): 9 of 117 heterozygotes
(8%) had symptoms associated with a retinal dystrophy,
without retinal pigmentary changes; 31 of 117 heterozygotes
(26%) had retinal pigmentary changes without symptoms; and
42 of 117 heterozygotes (36%) had both symptoms and retinal
pigmentary changes.
Of the heterozygotes with retinal pigmentary changes (n¼
73), peripheral and midperipheral pigmentations were more
marked in the inferior quadrants of the retina in 14 of 73 (19%).
Applying the fundus grading criteria to the last available
fundus examination, we were able to distinguish the fundus
grade for 117 of 125 heterozygotes (94%; Table). An evident
change in fundus grade with time was observed in 8 of 117
heterozygotes (7%) and was based either on the new
appearance of retinal pigmentary changes (n¼ 6) in the third
to fifth decade of life or on an increase of previously observed
pigmentary changes (n¼ 2) from one quadrant or hemisphere
to at least three quadrants in the fifth decade of life.
Intraindividual asymmetry in the presence or extent of
retinal pigmentary changes was noted in 11 of 117 heterozy-
gotes (9%).
Visual Acuity
BCVA in the better seeing eye was generally associated with
age (0.8% decline/y; P ¼ 0.002), and BCVA was lower in
individuals with myopia (P ¼ 0.006) and with a mutation in
exon 1-14 (P ¼ 0.0003), but was not significantly associated
with the presence of retinal pigmentary changes (P ¼ 0.17).
BCVA was impaired in at least one eye in 45 of 116 individuals
(39%; Fig. 1). Mildly impaired visual acuity and low vision in
the better seeing eye were seen from the second decade of
life onward, whereas blindness was observed from the sixth
decade of life onward. BCVA decline in heterozygotes at the
most severe end of the spectrum (i.e., full expression of the
RP or CORD phenotype) was 1.9%/y (P¼ 0.003). The median
BCVA in Dutch male RPGR hemizygotes who were related to
these affected female carriers was relatively lower (P ¼ 0.03)
than in the other male patients, despite no significant age
difference (P¼ 0.39). The decimal BCVA in female carriers at
the last visit, averaged between eyes, was lower in those with
exon 1-14 mutations (median BCVA, 0.55; IQR: 0.6; range,
light perception to 1.125) than in those with ORF15
mutations (median BCVA, 0.9; IQR: 0.5; range, light percep-
tion to 1.6; P ¼ 0.002). However, the median BCVA was also
lower in heterozygotes from RP pedigrees (P¼ 0.00001) than
in those from COD/CORD pedigrees, and mutations in exon
1-14 were almost exclusively found in RP pedigrees. We
therefore investigated these genotype–phenotype correla-
tions further by stratifying between heterozygotes from RP
pedigrees and COD/CORD pedigrees and analyzing geno-
type–phenotype correlations within those groups. After this
stratification, no difference between heterozygotes with exon
1-14 and those with ORF15 mutations was found (P ¼ 0.10).
Color vision testing identified a deuteranopic (n ¼ 3),
combination deuteranopic and tritanopic (n¼ 3), unspecified
(n ¼ 5), or total (n ¼ 1) deficiency in 12 of 45 (27%) of
subjects.
A strong intraindividual symmetry in BCVA was observed
(Spearman’s correlation coefficient ¼ 0.65; P < 0.00001). An
intraindividual difference in BCVA between eyes of ‡15 ETDRS
letters (0.3 logMAR) at two consecutive examinations or only
examination in the case of one BCVA measurement, was found
in 31 of 116 (27%) and was most likely attributable to
anisometropic amblyopia (interocular difference of ‡2 diop-
ters [D]; n¼10), amblyopia associated with strabismus (n¼3),
amblyopia with unclear cause (n¼4), asymmetry in cataract (n
¼ 1), unilateral stronger disease expression (n ¼ 5), or an
unknown cause (n ¼ 8). A myopic refractive error (below
0.75 D) was found in 74 of 101 (73%) heterozygotes (Table),
using the last phakic refractive error in the case of
pseudophakia (n ¼ 8) or laser-assisted in situ keratomileusis
(n ¼ 4). Myopia-associated posterior staphyloma (n ¼ 4),
lacquer cracks (n ¼ 4), Fuchs spot (n ¼ 1), and patchy
chorioretinal atrophy (n ¼ 8) were reported in 16 subjects.
Anisometropia was present in 34 of 101 (34%) subjects.
Full-Field ERG and Visual Field Findings
ERGs, available for 59 heterozygotes, showed significantly
reduced amplitudes in various patterns in 42 of 59 (71%)
heterozygotes (Table), with no significant age difference
between heterozygotes with normal and those with attenuated
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responses (P¼ 0.9). Pigmentary fundus changes were present
in 37 of 42 (88%) heterozygotes with significantly reduced ERG
amplitudes, and 32 of 42 (76%) had visual symptoms.
Heterozygotes with reduced scotopic or photopic amplitudes
were significantly (P¼ 0.005) more myopic (mean,8.4 D; SD,
6.1) than those with normal amplitudes (mean, 3.3 D; SD,
3.6), although mild (4 of 13), moderate (2 of 13), and high
myopia (3 of 13) were also found in those with normal ERG
amplitudes.
Between heterozygotes, little intrafamilial variability was
seen, as heterozygotes with abnormal ERGs tended to cluster
within families. However, intrafamilial differences between
heterozygotes and male hemizygotes were observed: five
heterozygotes from different pedigrees had a cone- or cone-
rod pattern on ERG, whereas their affected male relatives had
RP.
Goldmann visual fields, available for 53 heterozygotes (106
eyes), showed variable degrees of sensitivity reduction in 46 of
TABLE. Clinical Characteristics of RPGR Heterozygotes
Characteristics All (n ¼ 125)
Origin RP
Pedigree (n ¼ 83)*
Origin COD/CORD
Pedigree (n ¼ 37)* P Value
Exon 1-14, n (%) 42 (34)* 38 (46) – <0.00001
ORF15, n (%) 83 (66) 45 (54) 37 (100)
Median refractive error (IQR; range), D† 3.6
(8.6; 21.25 D þ4.13 D)
5.5
(8.4; 21.25 D þ4.13 D)
1.0
(3.4; 17.25 D þ2.38 D)
0.01
High myopia (< 6D), n (%) 36/102* (35) 31/68 (46) 5/29 (17) 0.007
Moderate myopia (3 D > SER ‡ 6 D), n (%) 22/102 (22) 17/68 (25) 4/29 (14)
Mild myopia (0.75 D > SER ‡ 3 D), n (%) 16/102 (16) 6/68 (9) 8/29 (28)
‡ 0.75 D 28/102 (27) 14/68 (21) 12/29 (41)
Cataract, n (%) 33/107 (31) 27/72 (38) 5/32 (16) 0.02
SPC, n 9 8 1
Other or unspecified, n 24 19 4
Fundoscopic examination
Optic disc pallor, n (%) 32/94 (34) 26/58 (45) 6/33 (18) 0.02
Peripapillary atrophy, n (%) 36/94 (38) 29/58 (50) 7/33 (21) 0.02
Vascular attenuation, n (%) 40/93 (43) 35/62 (56) 5/28 (18) 0.001
Fundus grade assessable 117* 79 34
Grade 0, n (%) 21 (17) 12 8
Grade 1, n (%) 11 (9) 6 4
Grade 0 or 1, n (%)‡ 12 (10) 8 4
Grade 2, n (%) 43 (34) 34 8
Grade 3 (%) 17 (14) 13 4
Grade 2 or 3, n (%)‡ 13* (10) 6 6
Pigment changes, any type, n (%) 73/117* (62) 53/79 (67) 17/34 (50) 0.10
Bone spicule-like/round, n (%) 46* (37) 39 6
Salt-and-pepper, n (%) 4 (4) 2 2
Macular RPE alterations/atrophy, n (%) 40 (32) 31 8 0.08
Mean age at macular RPE involvement 6 SD,
y (range)
43.6 6 17.5
(12.277.7)
44.1 6 18.2
(12.277.7)
43.2 6 15.8
(21.459.3)
0.90
RPE alterations in periphery, n (%) 37 (29) 23 14
Tigroid/tessellated fundus, n (%) 15 (12) 8 7
ERG pattern§ 59* 44 11
No abnormalities, n (%) 11 (19) 7 (11) 4 (36) 0.06j j
Subnormal/low-to-normal amplitudes, n (%) 6 (10)* 4 1
Electronegative, n (%)¶ 2 (3) 2 –
Rod-cone, n (%) 9 (15) 9 –
Reduced rods and cones, no predominance
specified, n (%)
19* (32) 17# 1
Cone-rod, n (%) 8 (14) 2 4
Isolated cone reduction, n (%) 2 (3) 1 1
Nondetectable, n (%) 2 (3) 2 –
Significant P values (<0.05) are indicated in bold. SER, spherical equivalent of the refractive error; SPC, subcapsularis posterior cataract.
* Five heterozygotes with mutations in exon 1-14 (n¼ 4) or ORF15 (n¼ 1) were not included in the columns distinguishing based on pedigree
(RP or COD/CORD), as the diagnosis in the pedigrees could not be established or confirmed in four subjects, and one heterozygote with a mutation
in exon 10 (deletion after exon 10) was from a mixed RP/CORD pedigree.
† Averaged between eyes.
‡ In 18 (20%) carriers, no distinction between fundus grades 0 and 1 (n¼ 9; 10%) or 2 and 3 (n¼ 9; 10%) could be made based on the notes in
the medical record. In seven (8%) heterozygotes, no sufficient data on their fundus appearance were available to estimate the fundus grade.
§ One of the heterozygotes with nondetectable responses had previously documented rod-cone responses. One heterozygote with
anisometropia had significantly reduced rod and cone amplitudes in her highly myopic eye and normal amplitudes in her mildly myopic eye.
j j Fisher’s exact test.
¶ Markedly reduced b-wave with a response resembling an electronegative ERG.
# One heterozygote had significantly reduced rod and cone amplitudes in one eye (OS), but normal amplitudes in OD. Other measures of visual
function (GVF, BCVA) in this subject showed marked asymmetry in favor of OD.
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53 subjects (87%; Supplementary Fig. S2; Supplementary Table
S3), with a unilateral sensitivity reduction in 2 subjects and
relatively more severely affected superior hemifields in 13
subjects. Age was associated with the I4e isopter size (decline
rate 4.9%/y; P¼ 0.012), but not with the V4e isopter size (P¼
0.06).
Of the 90 eyes with variable degrees of sensitivity
reduction, 69 (77%) had peripheral retinal pigment changes
or chorioretinal atrophy. Heterozygotes had a better preserved
visual field than their age-matched affected male relatives, with
three exceptions from one family (Supplementary Fig. S2).
Findings on Retinal Imaging
SD-OCT imaging of the macula in 47 heterozygotes showed a
preservation of all retinal layers in 22 subjects (15 of 22 with
peripheral retinal pigmentary changes; 4 of 22 with central
RPE alterations), but showed outer retinal attenuation in 25
heterozygotes (53%), with relative foveal sparing in 23 of these
subjects. There was no significant age difference between
heterozygotes with outer retinal attenuation on SD-OCT
(mean, 44.7 years; SD, 20.3; range, 11.7 to 80.0 years) and
those with normal outer retinas on SD-OCTs (mean, 37.2 years;
FIGURE 1. Bar chart of visual impairment category by fundus appearance and by decade of life. Visual impairment in the better (A) and worse (B)
seeing eye, stratified by fundus appearance. (C) Visual impairment in the better seeing eye, by decade of life, showing a general trend toward visual
impairment with increasing age, although the visual acuity in the better seeing eye remains favorable. (D) The relation of the BCVA in logMAR
between the right and left eye, showing a not fully linear relationship. The Spearman’s correlation coefficient, taking into account this nonlinear
relationship, showed a fair symmetry in visual acuity between eyes (0.64).
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FIGURE 2. Multimodal imaging illustrating the phenotypical spectrum of RPGR heterozygotes from pedigrees of RP. (A–C) The right eye of a 48-
year-old heterozygote (ORF15: c.2200G>T) with optimal BCVA, sectorial pigmentary changes consistent with RP (A). On FAF with a 308 field of
view (B), a radial pattern of different AF is clearly visible. FAF further shows small hyper-AF spots surrounded by a hypo-AF border that colocalize
with small hyporeflective ellipsoid zone irregularities on SD-OCT (C, green arrowheads). The appearance of a thick outer plexiform layer may
indicate a non–well-aligned scan. (D–F) The left eye of a 65-year-old highly myopic (11 D) heterozygote (exon 3: c.248-28_248-10del) with light
perception vision OU, showing a posterior staphyloma (D), an atrophic retina with partially obliterated vessels, and bone-spicule pigmentations in
the midperiphery (not shown). FAF with a 308 field of view (E) shows extensive patches of absent AF, but areas of normo-AF and hyper-AF are
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SD, 12.8; range, 14.3 to 59.8 years). Spearman’s correlation
testing showed no significant correlation between age and
central retinal thickness (CRT; P ¼ 0.81), foveal outer nuclear
layer (ONL) thickness (P ¼ 0.67), or thickness of the outer
retinal layers (P¼ 0.85). The degree of attenuation varied from
mild to moderate peripheral macular thinning of the ellipsoid
zone, the external limiting membrane, and/or the outer
nuclear layer (n ¼ 12), to a nearly complete absence of these
layers with only (para-)foveal remnants (n ¼ 8 complete RP/
CORD expression; Figs. 2, 3), or a peripheral macular absence
of these layers with only foveal and parafoveal granular
remnants (n ¼ 2; complete COD/CORD expression; Fig. 3),
whereas two remaining heterozygotes with RP had no foveal
remnants of these layers. One additional subject had unilateral
(para-)foveal attenuation of the ellipsoid zone after resolution
of a Fuchs spot. No anatomical correlates were observed for
the tapetal-like reflex on SD-OCT. Median CRT, ONL, and outer
retinal layers þ RPE complex thickness measured in the fovea
were 220 lm (IQR, 28; range, 126 to 292), 95 lm (IQR, 23;
range, 46 to 148), and 96 lm (IQR, 13; range, 42 to 115),
respectively. Subjects with symptoms and pigmentary fundus
changes had a significantly thinner foveal outer retina (P ¼
0.006), but no significantly thinner CRT (P¼ 0.28) or ONL (P¼
0.21).
FAF imaging in 40 heterozygotes showed abnormalities in
32 subjects (Figs. 2, 3), including a radial pattern in 26 of 40
and mottled, granular, or patchy hypo-autofluorescent changes
including in areas that appeared unaffected on fundoscopy or
fundus photography in the posterior pole in 13 of 40, in the
periphery in 17 of 40, and patchy areas of absent autofluores-
cence in 7 highly myopic subjects (Figs. 2, 3). Of the 26
carriers with a radial pattern on FAF, the tapetal-like reflex had
not been detected on fundoscopy or fundus photography in 15
of 26 (58%). In the eight carriers without a radial pattern or
other abnormalities on FAF, the fundus showed no RPE changes
(n ¼ 4), RPE atrophy in the periphery (n ¼ 1), granular RPE
alterations in the central macula (n ¼ 1), or had not been
documented (n ¼ 2).
DISCUSSION
In this retrospective cohort study, we describe the phenotypic
spectrum of 125 female carriers of pathogenic RPGR variants
from 49 pedigrees of RP and COD/CORD. This study is one of
the largest studies on female RPGR carriers to date, and we
identified a number of novel structural and functional
characteristics, also in comparison to affected male relatives.
Signs and/or symptoms were common (70%) both in the RP
and COD/CORD carrier groups in carriers of mutations in exon
1-14 and in carriers of ORF15 mutations, with complete
expression of RP or CORD in 29 heterozygotes (23%).
Although the longitudinal results are probably biased, as the
follow-up was significantly longer and more frequent in
heterozygotes with myopia or pigmentary changes, our results
indicate that clinically severe phenotypes are not rare in
heterozygous female RPGR mutation carriers.
Female carriers of X-linked retinal dystrophies have been
reported to express RP characteristics,21,22 sometimes partial
or sectorial, albeit in small cohorts.7,11,17,23 This variability has
challenged the ability to identify the accurate disease
inheritance mode in families with affected female patients.24–26
In the early stages of genetic counseling of an RP pedigree, the
presence of affected female subjects should raise suspicion of
both an autosomal–dominant and an X-linked inheritance
mode. In fact, typical RP fundus features, such as bone–
spicular or nummular intraretinal pigmentation, optic disc
pallor, and vascular attenuation, were common in this cohort,
expectedly more so in heterozygotes from RP pedigrees (49%,
44%, and 56%, respectively; Table) than in those from COD/
CORD pedigrees (18%, 18%, and 18%, respectively).
Previous reports have shown that female carriers of X-
linked COD/CORD usually show either no or minimal fundus
changes,14,27 but cases of heterozygotes displaying macular
RPE alterations have been described,15 and our cohort further
expands this phenotypic spectrum, showing the frequent
involvement of macular retina (32%; Table), including cases of
full COD or CORD expression.
Myopia was associated with a lower BCVA, and high myopia
(below 6 D) was found in a similar incidence as in the male
cohort we previously investigated (35% in heterozygotes
versus 38% in male hemizygotes), with 12% showing a
tessellated fundus, four cases of posterior staphyloma, and
eight cases of highly myopic patchy chorioretinal atrophy.
Although the reasons for the association between RPGR
mutations and high myopia remain unclear, a recent study
analyzing refractive errors in inherited retinal dystrophies has
postulated that the transport area between the inner and outer
segment (i.e., the location of protein RPGR), is one of the
critical sites for refractive error development.28 Mutations in
RP1 and RP2, encoding an outer segment protein and another
connecting cilium protein, respectively, have also been linked
to high myopia,29,30 further corroborating this hypothesis.
However, not all genes encoding connecting cilium proteins
are associated with myopia, and some have been associated
with hyperopia (e.g., CEP290 and RPGRIP1), and biallelic
mutations in these are generally associated with much more
extreme visual loss due to Leber congenital amaurosis.31,32 The
presence of (high) myopia in RPGR heterozygotes with no
photoreceptor dysfunction on ERG supports the notion that
photoreceptor degeneration and high myopia might be two
parts of the same disease, although the association between
high myopia and reduced rod/cone amplitudes would support
the concept of scleral remodeling stimulation by signals from
dysfunctional photoreceptors and/or more frequent near-
focusing due to reduced BCVA. However, the interpretation
of the latter is confounded by the association of high and
degenerative myopia with reduced ERG amplitudes.33
The occurrence of a BCVA below 20/200 in at least one eye
(13%; Fig. 1) in this cohort was higher than in an earlier
longitudinal report in a cohort of XLRP carriers from a
combination of genotyped and ungenotyped families, which
reported this BCVA in 2%.10 In keeping with earlier reports,
abnormal GVF (46 of 53; 87%) and ERG (42 of 59; 71%) results
visible. SD-OCT (F) shows atrophy of all retinal layers, and the ellipsoid zone and external limiting membrane are not discernible. The markedly
thinned, almost absent choroid points to an important myopic degenerative factor. (G–I) The left eye of a 46-year-old moderately myopic
heterozygote (ORF15: c.2536G>T) with RP and a decimal BCVA of 0.3/0.5. Her fundus shows vascular attenuation, bone–spicule pigmentation in
the midperiphery, and alterations of the RPE in the macula (G). FAF imaging with a 558 field of view (H) shows an oval zone of mottled hypo-AF
around the fovea and more coarsely mottled hypo-AF in the perimacula and midperiphery, mainly nasal to the optic disc. The corresponding SD-
OCT scan (I) shows generalized severe attenuation of the outer retinal layers, with only scattered granular remnants of the ellipsoid zone. The ONL
is nearly absent outside of the fovea. (J, K) The right eye of a 34-year-old highly myopic (16 D) heterozygote (ORF15: c.2010del), whose fundus
photograph (J) shows a paracentral patch of retinal atrophy, corresponding on FAF imaging with a 558 field of view (K) with a patch of absent AF.
FAF further shows a ring of relative hyper-AF surrounding a normal fovea and mottled areas of hypo-AF around the vascular arcade, more distinctly in
the inferior retina.
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FIGURE 3. Multimodal imaging illustrating the phenotypical spectrum of RPGR heterozygotes from pedigrees of CORD. (A–C) The left eye of a 32-
year-old heterozygote (ORF15: c.2426_2627del) with optimal BCVA, a tapetal-like reflex on fundus photography (A) and FAF with a 308 field of view
(B), and a normal appearance of the retina on SD-OCT (C). (D–F) The right eye of a highly myopic (13.5 D) 36-year-old heterozygote (ORF15:
c.3092del) with a CORD phenotype and a BCVA of 0.5/0.1, showing peripapillary atrophy and a paravascular patch of chorioretinal atrophy. On FAF
with a 308 field of view (E), mottled and granular hypo-AF changes are seen, predominantly along the vascular arcade, with a granular hypo-AF ring
around the central macula and a sharply demarcated patch of absent AF along the upper vascular arcade. A radial pattern can be discerned in the
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were more common than pigmentary changes (73 of 117; 62%)
or BCVA impairment (13%, 3%, and 9% for low vision, severe
visual impairment, or blind in one eye, respectively).10,11
However, GVF and ERG were consistently performed only in a
subset of heterozygotes, as was the case in this retrospective
cohort, and the availability of these test results may thus be
subject to bias, as additional testing may have mostly been
performed in heterozygotes with symptoms or signs of disease.
However, even when assuming that all heterozygotes without
additional testing would have no abnormalities, our study
shows that a relatively large proportion of heterozygotes
experience variable degrees of visual field constriction (46 of
125; 37%) or significant amplitude reduction on ERG (42 of
125; 34%).
Although there was noticeable intrafamilial variability in
certain cases, heterozygotes with signs and/or symptoms of
disease tended to originate from the same pedigrees. However,
this aggregation may be overestimated, as possible (non-
obligate) heterozygotes without signs or symptoms may never
seek specialist advice from a geneticist or ophthalmologist. The
intra- and interfamilial spectrum of severity in heterozygotes of
X-linked retinal disorders has been at least partially attributed
to the role of X-chromosome inactivation.34,35 Based on this X-
chromosome inactivation, Dobyns et al.36 proposed a pene-
trance and severity index for X-linked diseases, as opposed to
using the terminology of X-linked dominant, semidominant, or
recessive inheritance, as this concept is not based on X-
inactivation in humans but on the X-transcription speed and
dosage compensation in the Drosophila model. Random X
inactivation is proposed to occur early in embryonic develop-
ment, in each cell independently,37 and would result in a
mosaic pattern of cells expressing the normal and mutated
gene. Our finding of a radial pattern on the available FAF
images in 65% of the examined carriers, even in those who had
no tapetal-like reflex on fundoscopy, indicates that FAF may be
particularly helpful in detecting such retinal mosaicism. This
radial pattern on FAF would support the earlier suggestion that
X inactivation might not occur in each cell independently, but
in clusters of cells in a similar pattern,38 followed by a
centrifugal radial growth of the neuroretina during embryonic
development.8 However, random X inactivation does not fully
explain the clustering of nearly complete penetrance in several
families in this cohort. There may be a role for skewed X
inactivation, in which the mutant allele is disproportionally
(in)active. Extremely skewed X inactivation has been shown in
specific mutations in some nonretinal X-linked disease
genes,39,40 and has been in favor of the nonmutated allele.
Secondary X inactivation skewing may manifest through a
selective (dis)advantage for cells with the mutation-containing
X-chromosome,41 which may be hereditary.42 The relative
family-based, rather than mutation-based, aggregation of
affected heterozygotes in this cohort, along with cases of
intrafamilial variability, points to a highly likely role of genetic
and/or environmental modifiers, as well as potentially skewed
X inactivation. Intraindividual asymmetry was a recurring
finding in this cohort. Left–right asymmetry in X-chromosome
inactivation in several paired structures of the body, such as the
retina, has been observed, but the biological basis remains
unclear. Other than few reports on asymmetrical ERG
responses in small numbers of heterozygotes from X-linked
RP or COD/CORD pedigrees,17,43 this clinical asymmetry has
remained largely unexplored. We found a high general
correlation between the right and left eye in this cohort, but
notable asymmetry in fundus phenotype (9%), in V4e or I4e
size on GVF (20%), BCVA (26%), and refractive error (33%) was
still observed.
As 23% of heterozygotes display a complete RP or COD/
CORD phenotype, with a yearly BCVA decline rate of 1.9%, the
question ensues if these heterozygotes may benefit from future
therapeutic options. Recently, a submacular gene therapy trial
for male patients with RPGR-associated RP commenced,16 and
preclinical studies optimizing subretinal RPGR gene therapy
have focused on the typical male severe phenotype, which
includes an early onset.44 Inclusion of heterozygotes in gene
therapy trials may be challenging until safety and efficacy data
are available in male subjects, because male subjects are
consistently more severely affected. Nonetheless, in female
cases with full disease expression, the macular RPE was
frequently altered or atrophic (90% vs. 32% of the total cohort),
rendering the concept of gene therapy in affected heterozy-
gotes a possibly appropriate treatment option in the future.
Serious concerns in the inclusion of female subjects would
include the limited comparability to male patients, and the
definition of a window of therapeutic opportunity, further
complicated by the variability in disease onset and progression.
The mean age at which macular RPE involvement was first
documented was 43 years, and blind heterozygotes were in
their sixth or seventh decade of life, which would translate to a
wider window of opportunity in female patients than in the
male cohort.
Limitations of this study include its retrospective design,
which means that not all subjects had undergone all clinical
examinations, as not all clinical examinations were considered
relevant or feasible in the clinical setting. Although the
gathered data are useful, even from subjects with single visits,
potential bias should be taken into consideration. Furthermore,
as a subgroup of subjects (37 of 125) originated from COD/
CORD pedigrees, this compromises the generalizability of the
reported findings.
In summary, the findings in this study provide useful
insights for the genetic and clinical counselling of female
carriers and may have implications for ongoing and future
trials. This study displays the wide phenotypic spectrum for
RPGR heterozygotes and shows that signs and/or symptoms of
disease are common, although the visual prognosis is favorable
compared with affected males. Myopia is a significant concern
due to its effect on BCVA, as it is in affected male patients. A
substantial proportion of heterozygotes displays a complete RP
perimacular region around the hypo-AF ring. SD-OCT (F) shows severe extrafoveal and foveal attenuation of the outer retinal layers, ellipsoid zone,
and external limiting membrane, with some granular and mottled remnants of the hyperreflective outer retinal bands. Outside of the fovea, the ONL
is barely discernible. (G–I) The right eye of a 63-year-old mildly myopic heterozygote (ORF15: c.2575G>T) with CORD. Fundus photography (G)
shows extensive outer retinal atrophy in the posterior pole and (mid)periphery, with patches of relatively preserved retina, and bone–spicule
pigmentations in the (mid-)periphery, encroaching on the posterior pole. FAF with a 558 field of view (H) shows a large zone of hypo-AF in the
macula, encompassing the peripapillary region and extending into the midperiphery, surrounded by a hyper-AF border. The corresponding SD-OCT
scan (I) shows an overall attenuation of the outer retina, with granular remnants of the ellipsoid zone. The ONL is discernible in the fovea and direct
parafovea but is nearly absent in the perimacula. (J, K) The right eye of a 56-year-old highly myopic (14.5 D) heterozygote (ORF15: c.3092del;
maternal aunt of the subject in D–F with CORD, with a BCVA of 0.1 OU. FAF with a 558 field of view of the right eye (J) shows peripapillary atrophy,
sharply demarcated patches of absent AF along the upper and lower vascular arcade and below the vascular arcade, and a mottled decrease of AF in
the posterior pole and below the vascular arcade. Some radial pattern can be detected outside of the vascular pole. SD-OCT (K) shows an atrophic
ONL, a scarcely visible external limiting membrane, and a granular ellipsoid zone. As in Figure 2F, the thinned choroid points to an important
myopic degenerative factor.
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or COD/CORD phenotype, and further prospective natural
history studies are necessary to determine whether inclusion
in future (gene) therapeutic trials would be feasible and useful
in this subset of severely affected female RPGR mutation
carriers and which outcome measures would provide the most
sensitive detection of treatment effect.
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